2022
MP53-11 FOUR KALLIKREIN PANEL TESTING AMONG MEDICARE BENEFICIARIES UNDERGOING PROSTATE CANCER SCREENING
Leapman M, Long J, Wang R, Sprenkle P, Ma X, Gross C. MP53-11 FOUR KALLIKREIN PANEL TESTING AMONG MEDICARE BENEFICIARIES UNDERGOING PROSTATE CANCER SCREENING. Journal Of Urology 2022, 207: e899. DOI: 10.1097/ju.0000000000002628.11.Peer-Reviewed Original ResearchChanges in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening
Leapman MS, Wang R, Park H, Yu JB, Sprenkle PC, Cooperberg MR, Gross CP, Ma X. Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening. JAMA Oncology 2022, 8: 41-47. PMID: 34762100, PMCID: PMC8587214, DOI: 10.1001/jamaoncol.2021.5143.Peer-Reviewed Original ResearchConceptsProstate cancer screeningUS Preventive Services Task ForcePSA testingCancer screeningInterrupted time series analysisCohort studyUS Preventive Services Task Force (USPSTF) recommendationDraft statementLarge national cohort studyEligible beneficiariesPSA testing ratesRetrospective cohort studyRate of PSANational cohort studyProstate-specific antigenAge-adjusted ratesTask Force recommendationsUSPSTF guidelinesMedian ageGuideline changesProstate cancerMedian numberMAIN OUTCOMEClaims dataTesting rates
2021
PD50-11 CHANGES IN PSA SCREENING RELATIVE TO THE REVISED USPSTF GUIDANCE FOR PROSTATE CANCER SCREENING
Leapman M, Wang R, Gross C, Ma X. PD50-11 CHANGES IN PSA SCREENING RELATIVE TO THE REVISED USPSTF GUIDANCE FOR PROSTATE CANCER SCREENING. Journal Of Urology 2021, 206: e856-e856. DOI: 10.1097/ju.0000000000002072.11.Peer-Reviewed Original ResearchProstate cancer screeningCancer screeningRegional Adoption of Commercial Gene Expression Testing for Prostate Cancer
Leapman MS, Wang R, Ma S, Gross CP, Ma X. Regional Adoption of Commercial Gene Expression Testing for Prostate Cancer. JAMA Oncology 2021, 7: 52-58. PMID: 33237277, PMCID: PMC7689565, DOI: 10.1001/jamaoncol.2020.6086.Peer-Reviewed Original ResearchConceptsProstate cancerCohort studyGenomic testingTissue-based genomic testsProportion of patientsDynamic cohort studyProstate cancer careProstate cancer screeningHospital referral region levelCommercial health insuranceGene expression testingEligible patientsMedian ageCancer careCancer screeningInclusion criteriaFindings highlight factorsHRR levelMAIN OUTCOMEAdministrative claimsGroup 2Group 1Medicare beneficiariesPatientsMedian household income
2018
Prostate cancer risk factors in black and white men in the NIH-AARP Diet and Health Study
Layne TM, Graubard BI, Ma X, Mayne ST, Albanes D. Prostate cancer risk factors in black and white men in the NIH-AARP Diet and Health Study. Prostate Cancer And Prostatic Diseases 2018, 22: 91-100. PMID: 30108373, PMCID: PMC6676904, DOI: 10.1038/s41391-018-0070-9.Peer-Reviewed Original ResearchConceptsProstate cancer riskHazard ratioWhite menAdvanced diseaseBlack raceRisk factorsCancer riskHealth StudyRisk associationDietary vitamin D intakeProstate cancer risk factorsProportional hazards regression modelsBlack menNon-Hispanic white menPositive risk associationVitamin D intakeHistory of diabetesNIH-AARP DietCancer risk factorsProstate cancer screeningHazards regression modelsConfidence intervalsHealth-related factorsCancer risk associationsRace-specific associations
2017
Serum 25‐hydroxyvitamin D, vitamin D binding protein, and prostate cancer risk in black men
Layne TM, Weinstein SJ, Graubard BI, Ma X, Mayne ST, Albanes D. Serum 25‐hydroxyvitamin D, vitamin D binding protein, and prostate cancer risk in black men. Cancer 2017, 123: 2698-2704. PMID: 28369777, PMCID: PMC5498231, DOI: 10.1002/cncr.30634.Peer-Reviewed Original ResearchConceptsProstate cancer riskD binding proteinVitamin D statusCancer riskD statusOdds ratioProstate cancerLow vitamin D statusSerum DBPOvarian Cancer Screening TrialDecreased prostate cancer riskOverall prostate cancerCancer Screening TrialBlack menProstate cancer screeningApparent inverse associationConfidence intervalsVitamin D binding proteinConditional logistic regressionProstate cancer casesNonaggressive diseaseCohort entryCancer screeningBlood drawInverse association
2013
The cost implications of prostate cancer screening in the Medicare population
Ma X, Wang R, Long JB, Ross JS, Soulos PR, Yu JB, Makarov DV, Gold HT, Gross CP. The cost implications of prostate cancer screening in the Medicare population. Cancer 2013, 120: 96-102. PMID: 24122801, PMCID: PMC3867600, DOI: 10.1002/cncr.28373.Peer-Reviewed Original ResearchConceptsProstate cancerScreening costsAnnual screening costsPopulation-based cohortProstate cancer screeningHospital referral region levelMale Medicare beneficiariesProstate-specific antigenCancer screeningLowest quartileHRR levelMedicare populationMedicare beneficiariesOlder menNational feeCancerService Medicare programCancer diagnosisMenQuartilePSACost implicationsAnnual expenditureMedicare programBiopsy
2012
Impact of the 2008 US Preventive Services Task Force Recommendation to Discontinue Prostate Cancer Screening Among Male Medicare Beneficiaries
Ross JS, Wang R, Long JB, Gross CP, Ma X. Impact of the 2008 US Preventive Services Task Force Recommendation to Discontinue Prostate Cancer Screening Among Male Medicare Beneficiaries. JAMA Internal Medicine 2012, 172: 1601-1603. PMID: 22987029, PMCID: PMC3597450, DOI: 10.1001/archinternmed.2012.3726.Peer-Reviewed Original Research